Medicare Outpatient Coverage Of Natrecor Could Be Limited To Clinical Trials
Executive Summary
The Centers for Medicare & Medicaid Services' national coverage determination for Johnson & Johnson's Natrecor (nesiritide) will be one of the first opportunities for the agency to implement its "coverage with evidence development" policy
You may also be interested in...
Medicare Proposes To Cover J&J’s Natrecor For Labeled Indication Only
The Centers for Medicare & Medicaid Services is proposing to restrict Medicare coverage of Johnson & Johnson/Scios' Natrecor to its labeled indication for acutely decompensated heart failure, rather than provide wider coverage for the drug under a "coverage with evidence development" program
Medicare Proposes To Cover J&J’s Natrecor For Labeled Indication Only
The Centers for Medicare & Medicaid Services is proposing to restrict Medicare coverage of Johnson & Johnson/Scios' Natrecor to its labeled indication for acutely decompensated heart failure, rather than provide wider coverage for the drug under a "coverage with evidence development" program
CMS To Give More Specifics For Use Of Coverage With Evidence Development
The Centers for Medicare & Medicaid Services will offer greater clarity on when it will require data collection as a condition of Medicare Part B coverage in a second draft of its guidance on the topic